Koninklijke Phil Stock Price, News & Analysis

Royal Philips (NYSE: PHG) announced research affirming the efficacy of its BioTel Heart MCOT for detecting atrial fibrillation (AF) post-cryptogenic stroke. The study demonstrated that MCOT detected 4.6 times more AF cases than the implantable loop recorder (ILR) alone. Implementing MCOT resulted in an average cost reduction of $198,909 per patient, illustrating significant savings and improved detection rates. This research validates the 30-day MCOT program as a cost-effective standard of care for cryptogenic stroke patients, potentially averting further strokes through timely intervention.

On February 22, 2022, Royal Philips (NYSE: PHG) reported significant ESG achievements for 2021. The company improved the lives of 1.7 billion people, with 167 million in underserved communities. Circular revenues constituted 16% of sales, driven by healthcare informatics and services. Philips maintained its carbon neutrality in operations, reducing CO₂ emissions by 12%. The firm aims for 50% of suppliers to commit to science-based targets by 2025. Additionally, Philips reported a 29% waste reduction compared to 2020, highlighting its commitment to sustainability.

Royal Philips (NYSE: PHG) announced that its Philips Enterprise Viewer – Vue Motion and EMR Tasy have received the 2022 Best in KLAS awards, marking a significant achievement in health technology. Vue Motion was recognized as the best Universal Viewer for the fifth consecutive year, while EMR Tasy won for Acute Care EMR in Latin America. These awards highlight Philips’ commitment to advancing digital health transformation and improving patient care through innovative informatics solutions.

Royal Philips has enhanced its Lumify handheld ultrasound technology by introducing Pulse Wave Doppler, enabling comprehensive hemodynamic assessments for various medical professionals, including cardiologists and emergency care doctors. This upgrade allows for better quantification of blood flow and improved diagnostics across multiple specialties. Additionally, Lumify becomes the first handheld ultrasound to offer B-lines software, assisting in heart and lung evaluations, particularly for severe COVID-19 cases. This innovation aims to increase access to quality healthcare in underserved communities.

Royal Philips (NYSE: PHG) has entered a 10-year partnership with University Hospital Brandenburg an der Havel, valued at approximately EUR 18 million, to enhance its healthcare capabilities. This collaboration focuses on the supply of advanced diagnostic imaging solutions, including ultrasound and MRI, alongside the upgrading of hybrid operating rooms and interventional suites. The agreement also involves training and education for medical staff, aiming to improve patient outcomes and streamline operations.

Philips has launched the first full-service, at-home, 12-lead ECG solution tailored for decentralized clinical trials. This clinical-grade ECG aims to enhance patient recruitment, compliance, and retention by minimizing the necessity for site visits. With data readings comparable to traditional site-based ECGs, the innovative solution utilizes the PCA 500 ECG patch for secure, real-time data transmission. Philips’ advanced monitoring services have supported over 2,000 clinical trials globally. This new offering is already available in select markets across North America, Europe, and Asia.

On January 24, 2022, Royal Philips reported a challenging fourth quarter with sales of EUR 4.9 billion, reflecting a 10% comparable sales decline. The decline was attributed to supply chain challenges and COVID-19 related factors. Though income from continuing operations decreased to EUR 139 million from EUR 508 million in Q4 2020, adjusted EBITA stood at EUR 647 million, marking a drop from the previous year. Positive trends were seen in Diagnosis & Treatment with 4% order intake growth. For 2021, overall sales were EUR 17.2 billion, impacted by a decline in Connected Care. A dividend of EUR 0.85 per share was proposed.